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Abstract:
The recently discovered technique of deracemization by means of
attrition-induced grinding of a solid conglomerate in contact with
a solution wherein racemization occurs has been used with a
derivative of 2-chlorophenyl glycine, the key chiral component in
the synthesis of Clopidogrel (Plavix). Deracemization of the
racemate proceeds to a single enantiomer and in essentially
absolute enantiomeric excess. Further conversion of enantiomeri-
cally pure material to Clopidogrel was achieved in 88% yield.
Introduction
Racemizable conglomerates can be driven to enantiomeric
purity by proper choice of solid/solution contact and use of
attrition grinding.1 Ample evidence for the generality of this
remarkable observation is available.2 An obvious limitation to
technological application is the necessity that the racemate be
a conglomerate. Only about 5-10% of all crystalline organic
compounds occur as conglomerates.3 Design of conglomerates
from first principles is nearly impossible.4 We have recently
reported the deracemization by attrition-enhanced Ostwald
ripening of a derivative of naproxen known from the literature
to be a conglomerate so that a further search was not necessary.5
We describe here both a very simple and practical approach
for solution of the problem of rapid identification of conglomer-
ates together with application of the grinding technique to the
synthesis of Clopidogrel.
(S)-Clopidogrel (Plavix) 1 is a platelet aggregation inhibitor
used for treatment of ischemic strokes, heart attacks, athero-
sclerosis and also for the prevention of thrombosis after
placement of intracoronary artery stents. The Plavix market was
reported to be US$7.3 billion in 2007 up 19% relative to 2005.6
In patent procedures Clopidogrel is either resolved with camphor
sulfonic acid (CSA),7 or the intermediate 2-chlorophenylglycine
ester 2 (see Scheme 1) is resolved with tartaric acid.8 In either
approach the undesired enantiomer can be recycled by racem-
ization. Both 1 and 2 as free bases are oils at room temperature
and not suitable for deracemization as described above. On the
basis of our experience with the imines of amino acid amides
(usually solids and racemizable) we envisaged a route starting
from readily available racemic 2-chlorophenyl glycine (5,
Scheme 2) used as amide 3, which is converted reversibly to
imine 4. We proposed to make a small library of imines 4a-i
derived from 3 using various aromatic aldehydes (Scheme 2),
and to scan the library for conglomerate behaviour using second
harmonic generation (SHG)9 and small-scale deracemization
experiments.
Results
Second harmonic generation is a very fast method to scan
solids for noncentrosymmetric space groups.3a,9 A positive effect
is strongly indicative that the compound is a conglomerate, but
may not be considered a guarantee. Results of SHG observations
and nonoptimized grinding experiments are given in Table 1.
In this small library significant SHG effects were observed with
4a, 4c, and 4d. Compound 4a, obtained, it may be noted, from
relatively inexpensive benzaldehyde, deracemized immediately.
The failure to observe deracemization with 4c and 4d in these
scouting experiments is probably due to nonoptimized condi-
tions for crystallization. No attempt was made at this stage to
optimize conditions. The other imines are presumably racemic
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solution in contact with the solid: (a) Viedma, C. Phys. ReV. Lett.
2005, 94, 065504. for NaClO3 from supersaturated solution in contact
with solid. (b) Kondepudi, D. K.; Kaufman, R. J.; Singh, N. Science
1990, 250, 975. first demonstrated for an intrinsically chiral compound.
(c) Noorduin, W. L.; Izumi, T.; Millemaggi, A.; Leeman, M.; Meekes,
H.; van Enckevort, W. J. P.; Kellogg, R. M.; Kaptein, B.; Vlieg, E.;
Blackmond, D. G. J. Am. Chem. Soc. 2008, 130, 1158.
(2) (a) Cheung, P. S. M.; Gagnon, J.; Surprenant, J.; Tao, Y.; Xu, H.;
Cuccia, L. A. Chem. Commun. 2008, 987. (b) Tsogoeva, S.; Mauksch,
M. Angew. Chem., Int. Ed. 2009, 48, 590. (c) Viedma, C.; Ortiz, J. E.;
De Torres, T.; Izumi, T.; Blackmond, D. B. J. Am. Chem. Soc. 2008,
130, 15274. (d) Kaptein, B.; Noorduin, W. L.; Meekes, H.; van
Enckevort, W. J. P.; Kellogg, R. M.; Vlieg, E. Angew. Chem., Int.
Ed. 2008, 47, 7226.
(3) (a) Coquerel, G. Top. Curr. Chem. 2007, 269, 1–51. (b) Jacques, J.;
Collet, A.; Wilen, S. Enantiomers, Racemates and Resolutions; Krieger
Pub Co: Malabar, Florida, reprint, 1994; pp 10-20.
(4) See for example: (a) Perez-Garcia, L.; Amabilino, D. B. Chem. Soc.
ReV. 2007, 36, 941. (b) Leusen, F. Cryst. Growth Des. 2007, 7, 56.
(5) Noorduin, W. L.; Kaptein, B.; Meekes, H.; van Enckevort, W. J. P.;
Kellogg, R. M.; Vlieg, E. Angew. Chem., Int. Ed. 2009, 48, 4581.
(6) MS Global insights, from www.imshealth.com.
(7) (a) (Teva Pharmaceutical Industries). U.S. Patent 6,800,759, 2004. (b)
(Teva Pharmaceutical Industries). U.S. Patent 6,737,411, 2004. (c) U.S.
Patent 4,847,265, 1989. (d) (USV Ltd.). U.S. Patent 6,074,242, 2006.
(e) Wang, L.; Shen, J.; Tang, Y.; Chen, Y.; Wang, W.; Cai, Z.; Du,
Z. Org. Process Res. DeV. 2007, 11, 487.
(8) (a) (USV Ltd.). U.S. Patent 2004073057, 2004. (b) Srinivasa Reddy,
B. WO2006003671, 2006. (c) Eswaraiah, S.; Raghupathi Reddy, A.;
Goverdhan, G.; Lokeswara Rao, M. U.S. Patent 2007225320, 2007.
(9) Galland, A.; Dupray, V.; Berto, B.; Morin-Grognet, S.; Sanselme, M.;
Atmani, H.; Coquerel, G. Cryst. Growth Des. 2009, 9, 2713.
Organic Process Research & Development 2009, 13, 1195–1198
10.1021/op900243c CCC: $40.75  2009 American Chemical Society Vol. 13, No. 6, 2009 / Organic Process Research & Development • 1195
Published on Web 11/04/2009
compounds that cannot be expected to deracemize. Subse-
quently, we also established unambiguously that 4a is a
conglomerate by single-crystal structure determination of the
racemate (crystallographic data for 4a (CCDC 734087) can be
downloaded free of charge via www.ccdc.cam.ac.uk/conts/
retrieving.hmtl (or obtained from the Cambridge Crystal-
lographic Data Centre, 12 Union Road, Cambridge CB21EZ,
UK; fax (+44) 1223033; e-mail deposit@ccdc.cam.ac.uk)).
Optimal conditions for the deracemization of 4a
involved heating with 1,8-diazabicyclo[5.4.0]undec-7-ene
(DBU) as racemizing agent until complete dissolution at
70 °C, followed by cooling to 20 °C (0.1 °C ·min-1) with
vigorous stirring in the presence of glass beads for attrition
and to allow secondary nucleation to propagate the first
formed chirality.10 The enantiomeric excess (ee) reached
∼93% after a single night and went to >98% ee after
stirring an additional day. In five experiments the (S)-
enantiomer of 4a was obtained four times. On use of
isothermal grinding of a saturated solution in contact with
solid1c the (S)-enantiomer was obtained five times from
five experiments. This tendency towards nonrandom
behaviour follows previous observations for another
imine,1c which in more than 100 experiments always gave
the same enantiomer, (R) in that case. The presence of
minor amounts of chiral impurities, perhaps of natural
origin, is a possible explanation.
For preparative purposes the deracemization was carried out
on a 35 g scale. A few crystals of (S)-4a were added to ensure
that the (S)-enantiomer would be formed.1b An ee of >99.5%
with a yield of 80% was obtained overnight. For the synthesis
of Clopidogrel (S)-3a was converted to methyl ester (S)-2. Direct
conversion with H2SO4 gave many side products, probably due
to liberated benzaldehyde. Therefore, the benzaldehyde was first
removed by treatment of imine 4a with aqueous HCl in acetone,
which results in crystallization of the (S)-amide 3 as the HCl
salt.12 Subsequently the amide was converted to (S)-2 with
H2SO4 in MeOH.13 This free amino acid ester 2 is sensitive to
racemisation and must be stored as salt or used immediately in
the next reaction. The ee remained >99%. Reaction with dibro-
mide 6 gave (S)-Clopidogrel in 88% yield with an ee of >99%
(Scheme 3).
Conclusions
This short synthesis of an enantiomerically pure popular drug
without any chiral aid demonstrates the practical potential of
this new approach for preparing pure enantiomers. Measure-
ments by SHG provide a remarkably simple solution to the
problem of finding a suitable conglomerate by fast screening
of small libraries. We expect further improvements in and
applications of this new technology.
Experimental Section
(+/-)-2-Chlorophenylglycine Methyl Ester Hydrochlo-
ride (2 ·HCl). To 2-chlorophenylglycine 2 (100 g, 539 mmol)
in MeOH (270 mL) was added SOCl2 (47 mL, 647 mmol, 1.2
equiv) dropwise. After complete addition, the mixture was
stirred overnight at room temperature and subsequently heated
with a hot water bath for 3 h. Complete conversion was
indicated by NMR analysis. About 50 mL of the MeOH solvent
was evaporated, and the remaining reaction mixture was poured
in tert-butyl methyl ether (TBME, 700 mL). The resulting white
solid was collected by filtration and was washed with TBME
to give, after drying, ester 2 ·HCl (120.3 g, 510 mmol, 95%)
as a white solid.
(10) (a) Leeman, M.; Noorduin, W. L.; Kaptein, B.; Vlieg, E.; Meekes,
H.; van Enckevort, W. J. P. Zwaagstra, K.; de Gooijer, J. M.; Boer,,
K.; Kellogg, R. M. 2009. Manuscripted submitted. (b) This procedure
resembles the Kondepudi approach1b in that conglomerate 4a with
DBU is completely dissolved and then allowed to cool slowly with
attrition grinding. The first primary nucleation event from the
supersaturated solution of conglomerate is thought to provide a crystal
of single chirality and that chirality is propagated by secondary
nucleation aided by grinding (attrition of the crystal) as the solution
is cooled further. Deracemization was also easily achieved by
isothermal grinding from saturated solution1c in an ultrasound bath.11
The cooling procedure described here is technically somewhat easier
to carry out on large scale.
(11) Noorduin, W. L.; Meekes, H.; van Enckevort, W. J. P.; Millemaggi,
A.; Leeman, M.; Kaptein, B.; Kellogg, R. M.; Vlieg, E. Angew. Chem.,
Int. Ed. 2008, 47, 6445.
(12) van Lingen, H. L.; van de Mortel, J. K. W.; Hekking, K. F. W.; van
Delft, F. L.; Sonke, T.; Rutjes, F. P. J. T. Eur. J. Org. Chem. 2003,
317–324.
(13) (Sanofi-Synthelabo). U.S. Patent 6,670,486, 2005.
Scheme 1. Retrosynthetic approach to clopidogrel 1
Scheme 2. Synthesis of the Schiff basesa
a Reagents and conditions: a) SOCl2/MeOH (95%); NH3 (81%); c) RCHO/
Na2SO4 (90% for 4a).
Table 1. Results of second harmonic generation
measurements for 4a-i
entry R ) SHGa
ee in first test
(%)
1 Ph (4a) large SHG effect 33
2 2-tolyl (4b) no SHG effect 0
3 2-chlorophenyl (4c) largeSHG effect 0
4 2-bromophenyl (4d) large SHG effect 0
5 2-nitrophenyl (4e) small SHG effect b
6 2-benzyloxyphenyl(4f) no SHG effect 0
7 1-naphthyl (4g) small SHG effect 0
8 2-pyridyl (4h) small SHG effect b
9 2,5-difluorophenyl (4i) no SHG effect b
a Second harmonic generation. b Deracemization not attempted.
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1H NMR (DMSO-d6) δ 9.36 (2H, b), 7.67(1H, m), 7.57 (1H,
m), 7.45 (2H, m), 5.44 (1H, s) 3.76 (3H, s); 13C NMR (DMSO-
d6) δ 168.7, 134.0, 132.1, 131.1, 130.7, 130.5, 128.7, 54.1, 53.0;
[M + 1] (TOF/ESI) calculated for C9 H10NO2Cl: 200.05, found:
200.1.
(+/-)-2-Chlorophenylglycinamide (3). To ester 2 ·HCl
(100 g, 424 mmol) was added concentrated aqueous ammonia
(315 mL), and the resulting mixture was stirred overnight at
room temperature. The mixture was cooled with ice, and the
solids were collected by filtration, washed with water, and
stripped 3× with toluene to give 57.2 g of amide 3. The mother
liquor was extracted with dichloromethane (2 × 300 mL), dried
over Na2SO4, combined with the solid amide, and concentrated
to give amide 3 (63.6 g, 344 mmol, 81%) as a white solid.
1H NMR (DMSO-d6) δ 7.22-7.46 (5H, m), 7.18 (1H, b),
4.61 (1H, s), 2.31 (2H, b); 13C NMR (DMSO-d6) δ 175.3, 141.3,
133.3, 129.8, 129.5, 129.2, 127.8, 56.8; [M + 1] (TOF/ESI)
calculated: 185.05, found: 185.1.
(+/-)-2-(Benzylideneamino)-2-(2-chlorophenyl)aceta-
mide (4a). To amide 3 (58.7 g, 318 mmol) in dichloromethane
(DCM, 480 mL) was added benzaldehyde (35.3 mL, 350 mmol,
1.1 equiv) and Na2SO4 (73.4 g, 517 mmol, 1.63 equiv), and
the mixture was stirred overnight at room temperature. The
mixture was then heated with a hot water bath, and the solids
were removed by filtration. The residue was washed with warm
dichloromethane, and the combined mother liquors were
concentrated to give 88.3 g, 324 mmol crude imine 4a, which
was recrystallized from CH3CN (500 mL) to give 4a (77.9 g,
286 mmol, 90%) as a white solid.
1H NMR (DMSO-d6) δ 8.45 (1H, s), 7.87 (2H, dd), 7.63,
(1H, dd), 7.44-7.51 (6H, m), 7.32-7.38 (2H, m), 5.43 (1H,
s); 13C NMR (DMSO-d6) δ 172.1, 164.17, 138.1, 136.3, 133.4,
132.0, 130.9, 130.0, 129.8, 129.4, 129.2, 128.0, 73.6; [M + 1]
(TOF/ESI) calculated: 273.08, found: 273.2. The imines 3b-i
were prepared in a similar manner.
Deracemization Following Protocol of ref 10. (S)-(E)-2-
(Benzylideneamino)-2-(2-chlorophenyl)acetamide (4a). In a
1 L round-bottom flask with a 5 × 2 cm stirring egg was loaded
racemic-imine 4a (35 g, 128 mmol). MeCN (315 mL) and the
mixture were stirred at 1050 rpm. Glass beads (borosilicate,
0.2 mm, 87.5 g) were added, followed by the addition of DBU
(5.1 mL, 38.5 mmol, 0.3 equiv). The mixture was heated to 70
°C to form a homogeneous solution and subsequently cooled
to 20 °C with a rate of 0.1 °C/min using a thermostat (Huber
ministat cc). To the mixture were added a few milligram-sized
crystals of enantiopure imine 4a, obtained in a previous
experiment, at 68, 67, 66, and 64 °C. After stirring overnight
at 20 °C, chiral HPLC analysis revealed an ee > 99.5%, and
the solids were collected by filtration and washed with TBME
to give (S)-4a (115.6 g, including glass beads, 28.1 g, 103 mmol,
corrected, 80%) as a white solid.
Deracemization Following Isothermal Protocol of ref 1c.
(S)-(E)-2-(Benzylideneamino)-2-(2-chlorophenyl)aceta-
mide (4a). A scintillisation vial was charged with 2 mm glass
beads (10 g), Schiff-base 3a (389 mg, 1.43 mmol) and MeCN
(3.5 mL). The flask was placed in an ultrasonic bath, fitted with
a thermostat (keeping the temperature at 20 °C), and was
sonicated for 5 min. 1,8-Diazabicyclo[5.4.0]undec-7-ene (DBU,
0.10 g, 0.76 mmol, 0.53 equiv) was added, and the mixture
was sonicated at 20 °C overnight. After 1 night, ee was >80%,
after 2 nights ee was 91-98%. This experiment was carried
out as described above five times, and each time similar results
were obtained; in all cases the (S)-enantiomer of 4a was
obtained.
(S)-2-Chlorophenylglycinamide Hydrochloride (4 ·HCl).
To (S)-4a (28.0 g, 103 mmol) was added a mixture of
concentrated aqueous HCl (10.1 mL) and acetone (1.8 L), and
the resulting mixture was stirred for 1 h at room temperature.
The suspension was decanted from the glass beads from the
previous step, and the solids were collected by filtration, washed
with acetone, and dried to give (S)-3 ·HCl (21.6 g, 97 mmol,
95%) as a white solid.
1H NMR (DMSO-d6) δ 8.60 (3H, b), 7.75 (2H, d),
7.46-7.62 (m, 4H), 5.14 (1H, s); 13C NMR (DMSO-d6) δ
168.6, 134.2, 132.4, 131.7, 130.5, 130.2, 128.4, 53.0; [M + 1]
(TOF/ESI) calculated C8H9ON2Cl: 185.05, found: 185.0.
(S)-2-Chlorophenylglycine Methyl Ester (2). H2SO4 (26.0
mL, 487 mmol, 5 equiv) was added dropwise under ice cooling
to MeOH, and the resulting mixture was heated at reflux for
30 min. Amide (S)-3 ·HCl (21.6 g, 97 mmol) was added, and
the resulting mixture was stirred for 4 h. at reflux and then
overnight at room temperature. After NMR analysis revealed
complete conversion, MeOH was evaporated, and water (175
mL) was added. The aqueous layer was basified with 1 M
NaOH and extracted with DCE (3 × 50 mL). The combined
organic layers were washed with water (50 mL), dried over
Na2SO4, and concentrated to give (S)-2 (16.9 g, 85 mmol, 94%)
as a pale oil.
1H NMR (DMSO-d6) δ 7.48 (1H, dd), 7.42 (1H, dd),
7.26-7.7.36 (2H, m), 4.84 (1H, s), 3.58 (3H, s); 13C NMR
(DMSO-d6) δ 174.4, 139.3, 133.0, 130.0, 129.8, 129.6, 128.1,
56.2, 52.7; [M + 1] (TOF/ESI) calculated: 200.05, found: 200.1.
(S)-Clopidogrel (1). To 2-(2-bromoethyl)-3-(bromometh-
yl)thiophene, prepared by a literature procedure,14 (4.3 g, 15.1
mmol) in MeCN (45 mL) was added a mixture of ester (S)-2
(3.3 g, 17.8 mmol, 1.18 equiv) and di-isopropylethyl amine
(14) (Patent Hanmi Pharm. Co.). WO2005/87779, 2005.
Scheme 3. Synthesis of clopidogrela
a Reagents and conditions: a) HCl/acetone (95%); b) H2SO4/MeOH (94%); c) 6/MeCN (95%, ee > 99%).
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(DIPEA, 4.4 mL, 26.7 mmol, 1.77 equiv) in MeCN (20 mL)
dropwise, and the resulting mixture was heated at reflux
overnight. The mixture was concentrated, and the residue was
taken up in EtOAc (80 mL) and washed with water (2x 60
mL), brine (60 mL), dried over Na2SO4, and concentrated to
give clopidogrel 1 (4.3 g, 13.4 mmol, 88%) as a yellow oil
with a purity of 94-95% according to HPLC and an ee >99%
determined by chiral HPLC.
1H NMR (CDCl3) δ 7.7 (1H, m), 7.41 (1H, m), 7.24-7.32
(2H, m), 7.06 (1H, d), 6.67 (1H, d), 4.93 (1H, s), 3.61-3.79
(5H, m), 2.89 (4H, bs); 13C NMR (CDCl3) δ 171.6, 134.9,
134.1, 133.5, 133.5, 130.2, 130.0, 129.7, 127.4, 125.5, 123.0,
68.1, 52.4, 50.9, 48.5, 25.8; [M + 1] (API/ES) calculated:
322.07, found: 322.0.
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